



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

|                                |   |           |
|--------------------------------|---|-----------|
| <b>Summary for ARTG Entry:</b> | 352660  | Starter B |
| <b>ARTG entry for</b>          | Medicine Listed   |           |
| <b>Sponsor</b>                 | MTHFR Support Australia Pty Ltd                           |           |
| <b>Postal Address</b>          | PO Box 1265, Neutral Bay Junction, NSW, 2089<br>Australia |           |
| <b>ARTG Start Date</b>         | 7/01/2021   |           |
| <b>Product Category</b>        | Medicine  |           |
| <b>Status</b>                  | Active  |           |
| <b>Approval Area</b>           | Listed Medicines  |           |

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Starter B

|                     |                         |                       |           |
|---------------------|-------------------------|-----------------------|-----------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 7/01/2021 |
|---------------------|-------------------------|-----------------------|-----------|

### Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Maintain/support energy levels
- Helps convert (state food) into energy
- Maintain/support energy production
- Maintain/support healthy eye function
- Maintain/support eye health
- Maintain/support body mucous membrane health
- Maintain/support general health and wellbeing
- Maintain/support hair growth
- Maintain/support hair health
- Aid/assist nail growth
- Maintain/support nail health/strength/thickness
- Aid/assist/helps connective tissue production/formation
- Maintain/support healthy body tissues
- Aid/assist healthy red blood cell production
- Maintain/support red blood cell health
- Helps maintain/support haemoglobin formation/synthesis
- Maintain/support heart health
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Maintain/support muscle function
- Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
- Aids/assists the body to cope with environmental stress
- Support healthy stress response in the body
- Maintain/support nerve conduction

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Aid/assist/helps synthesis of neurotransmitters  
 Maintain/support nervous system health  
 Maintain/support nervous system function  
 Maintain/support skin health

**Indication Requirements**

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

|  |                      |
|--|----------------------|
| <b>Biotin</b>                            | <b>500 microgram</b> |
| <b>calcium pantothenate</b>              | <b>196.51 mg</b>     |
| Equivalent: pantothenic acid             | 180 mg               |
| <b>nicotinamide</b>                      | <b>130 mg</b>        |
| <b>pyridoxal 5-phosphate monohydrate</b> | <b>23.51 mg</b>      |
| Equivalent: pyridoxine                   | 15 mg                |
| <b>riboflavin sodium phosphate</b>       | <b>25 mg</b>         |
| Equivalent: riboflavin                   | 19.67 mg             |
| <b>thiamine hydrochloride</b>            | <b>63.55 mg</b>      |
| Equivalent: thiamine                     | 50 mg                |

**Other Ingredients (Excipients)**

**ascorbyl palmitate**

**colloidal anhydrous silica**

**disodium edetate**

**gellan gum**

**hypromellose**

**leucine**

**potable water**

**potassium acetate**

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.